Literature DB >> 16239385

The British Society for Rheumatology biologics register.

K Watson1, D Symmons, I Griffiths, A Silman.   

Abstract

The British Society for Rheumatology (BSR) established a nationwide register for patients with rheumatological disorders treated with biologic agents. The register is designed as a national prospective study whose primary purpose is to assess long term toxicity from the use of these agents in routine practice. In addition, the data will be capable of addressing the benefits from their use in relation to their toxicity. One specific feature of the BSR register is the recruitment and collection of data from a parallel comparison group, comprising patients with active rheumatoid arthritis treated with conventional disease modifying agents. Both class specific and drug specific analyses of the group treated with biologicals are planned.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239385      PMCID: PMC1766913          DOI: 10.1136/ard.2005.042499

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

2.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors:  E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal:  BMJ       Date:  1998-07-18

3.  Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.

Authors:  Karin Ekström; Henrik Hjalgrim; Lena Brandt; Eva Baecklund; Lars Klareskog; Anders Ekbom; Johan Askling
Journal:  Arthritis Rheum       Date:  2003-04

Review 4.  Rheumatoid arthritis and malignant lymphomas.

Authors:  Eva Baecklund; Johan Askling; Richard Rosenquist; Anders Ekbom; Lars Klareskog
Journal:  Curr Opin Rheumatol       Date:  2004-05       Impact factor: 5.006

5.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2004-06
  5 in total
  27 in total

1.  Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.

Authors:  Alasdair M Breckenridge; Ross A Breckenridge; Carl C Peck
Journal:  Br J Clin Pharmacol       Date:  2019-07-10       Impact factor: 4.335

Review 2.  Biologics registers in RA: methodological aspects, current role and future applications.

Authors:  Elena Nikiphorou; Maya H Buch; Kimme L Hyrich
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

3.  Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 4.  Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.

Authors:  Beáta J Radovits; Wietske Kievit; Roland F J M Laan
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis.

Authors:  Thomas R P Taylor; James Galloway; Rebecca Davies; Kimme Hyrich; Ruth Dobson
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-04-16

6.  Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K D Watson; M Lunt; L K Mercer; K L Hyrich; D P M Symmons
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

7.  Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Authors:  James B Galloway; Kimme L Hyrich; Louise K Mercer; William G Dixon; Bo Fu; Andrew P Ustianowski; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580

8.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103

9.  Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis.

Authors:  Samuel Hawley; René Cordtz; Lene Dreyer; Christopher J Edwards; Nigel K Arden; Antonella Delmestri; Alan Silman; Cyrus Cooper; Andrew Judge; Daniel Prieto-Alhambra
Journal:  Semin Arthritis Rheum       Date:  2017-09-23       Impact factor: 5.532

10.  Implementing an automated monitoring process in a digital, longitudinal observational cohort study.

Authors:  Lisa Lindner; Anja Weiß; Andreas Reich; Siegfried Kindler; Frank Behrens; Jürgen Braun; Joachim Listing; Georg Schett; Joachim Sieper; Anja Strangfeld; Anne C Regierer
Journal:  Arthritis Res Ther       Date:  2021-07-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.